Secondary outcome measures
SE
SECONDARY
As shown in Table The subgroup analysis for the secondary outcome measures focused on the female group, because, as aforementioned, the sample size of the male group appeared too small. Among the female patients, the benzoate 750 group excelled the placebo group in CIBIC‐plus at endpoint (estimate = −0.38, SE = 0.20, Among the female patients, the four treatment groups did not differ significantly in changing the performances in the additional cognition composite (not shown).